METTL3 and hepatocellular carcinoma: Besides, we discovered that HCC patients with higher METTL3 expression have shorter overall survival (OS) time, relapse-free survival (RFS) time, progression-free survival (PFS) time, and disease-specific survival (DSS) time compared to those with low METTL3 expression (Figure 1F).